Clinical chart reviews suggest adding a rotational chair device to therapy sped concussion recovery up to eightfold in patients with persistent symptoms.
Multi-site retrospective reviews examined chronic post-concussion cases treated with GyroStim, a computer-controlled, multi-axis rotational chair, alongside standard rehabilitation.
Higher treatment frequency was linked to faster improvement, indicating a dose-response effect.
The reviews were completed by concussion rehabilitation specialists at clinics in North Carolina and Florida.
At AVORA Health in Asheville, North Carolina, clinical director Dr Kim Fox, whose clinic specialises in complex vestibular disorders (conditions affecting the balance system), conducted one review.
The data indicated that when GyroStim was delivered at an average of four or more sessions per week alongside conventional therapies, some patients achieved rehabilitation rates more than eight times faster than standard care alone.
Dr Fox said: “GyroStim has taken our brain injury rehabilitation programme to an entirely new level.
“This comprehensive approach allows us to apply progressive, patient-specific challenges that engage visual, vestibular, proprioceptive, motor, and cognitive pathways within a controlled environment.
“When used in combination with physical therapy, we have achieved gains in shorter durations and have helped patients break through rehabilitation plateaus.”
Vestibular refers to the balance system; proprioceptive relates to the body’s sense of position and movement.
In Tallahassee, Florida, Dr Bill Heyser, clinical director of Heyser Chiropractic Neurology, reported similar findings from a retrospective review of patients with persistent post-concussion syndrome.
Dr Heyser said: “Before GyroStim, we were limited to targeting one sensorimotor system at a time. With GyroStim we can activate, stimulate, and retrain multiple sensory and motor systems simultaneously. This integrated approach enhances communication between the brain and body and has translated into faster, more complete recovery for our concussion patients.”
Key observations included that high-density treatment (four or more sessions per week) was associated with up to eight times the rehabilitation rate of conventional therapy alone, and that a statistically significant dose-response relationship was seen.
One example cited was US pentathlete Tyler Evans, the 2025 national champion. After a training concussion in January 2026, he began GyroStim treatment two days later and reported near-complete symptom resolution within four days.
Evans said: “In the past, my concussion recoveries have been brutally slow, with symptoms lingering for up to six months. This time, GyroStim dramatically accelerated my recovery. I was over it in just four days.”
Concussions affect millions of people in the US each year. Despite standard therapies, many experience symptoms for months or years.
The US Centers for Disease Control and Prevention estimates the condition costs billions of dollars annually in lost wages and healthcare.
Building on the chart-review findings, Dr Ben Siebert, president of NeuroScience Group and clinical director of the Neuroscience concussion clinic in Appleton, Wisconsin, is launching a large, IRB-approved clinical study to evaluate GyroStim’s efficacy.
An institutional review board oversees research involving people to ensure ethical standards.
Dr Siebert said: “For the past two years, we’ve seen firsthand how GyroStim accelerates recovery and enhances functional restoration.
“We believe GyroStim represents a tremendous advancement in concussion care; we’re excited to contribute prospective scientific evidence to further validate this treatment modality.”
